MX2022013187A - Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso. - Google Patents

Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.

Info

Publication number
MX2022013187A
MX2022013187A MX2022013187A MX2022013187A MX2022013187A MX 2022013187 A MX2022013187 A MX 2022013187A MX 2022013187 A MX2022013187 A MX 2022013187A MX 2022013187 A MX2022013187 A MX 2022013187A MX 2022013187 A MX2022013187 A MX 2022013187A
Authority
MX
Mexico
Prior art keywords
interest
rna
target sequence
methods
rgn
Prior art date
Application number
MX2022013187A
Other languages
English (en)
Inventor
Tyson D Bowen
Tedd D Elich
Alexandra Briner Crawley
Michael Coyle
Original Assignee
Lifeedit Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifeedit Therapeutics Inc filed Critical Lifeedit Therapeutics Inc
Publication of MX2022013187A publication Critical patent/MX2022013187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan composiciones y métodos para unirse a una secuencia objetivo de interés. Las composiciones encuentran uso para escindir o modificar una secuencia objetivo de interés, visualización de una secuencia objetivo de interés y modificar la expresión de una secuencia de interés. Las composiciones comprenden polipéptidos de nucleasa guiada por ARN (RGN), ARN CRISPR, ARN CRISPR transactivador, ARN guía y moléculas de ácido nucleico que codifican los mismos. También se proporcionan vectores y células hospedoras que comprenden las moléculas de ácido nucleico. Se proporcionan además sistemas RGN para unir una secuencia objetivo de interés, en los que el sistema RGN comprende un polipéptido nucleasa guiado por ARN y uno o más ARN guía.
MX2022013187A 2020-04-24 2021-04-23 Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso. MX2022013187A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014970P 2020-04-24 2020-04-24
US202063077211P 2020-09-11 2020-09-11
PCT/US2021/028843 WO2021217002A1 (en) 2020-04-24 2021-04-23 Rna-guided nucleases and active fragments and variants thereof and methods of use

Publications (1)

Publication Number Publication Date
MX2022013187A true MX2022013187A (es) 2022-11-14

Family

ID=75919401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013187A MX2022013187A (es) 2020-04-24 2021-04-23 Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.

Country Status (12)

Country Link
US (4) US20230175018A1 (es)
EP (2) EP4118198A1 (es)
JP (1) JP2023516226A (es)
KR (1) KR20230014700A (es)
CN (1) CN116096879A (es)
AU (1) AU2021258273A1 (es)
BR (1) BR112022021459A2 (es)
CA (1) CA3174124A1 (es)
IL (1) IL297500A (es)
MX (1) MX2022013187A (es)
TW (1) TW202208626A (es)
WO (1) WO2021217002A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300649A (zh) 2021-03-22 2023-01-01 美商生命編輯治療學公司 Ｄｎａ修飾酶及活性片段及其變體及使用方法
CA3173953A1 (en) 2021-06-11 2023-12-10 Tyson D. BOWEN Rna polymerase iii promoters and methods of use
WO2024033901A1 (en) 2022-08-12 2024-02-15 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
WO2024095245A2 (en) 2022-11-04 2024-05-10 LifeEDIT Therapeutics, Inc. Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
WO2024127370A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use
WO2024127369A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US457A (en) 1837-11-11 Caleb slade
US10167A (en) 1853-10-25 Soda-jountaiet
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5569597A (en) 1985-05-13 1996-10-29 Ciba Geigy Corp. Methods of inserting viral DNA into plant material
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4853331A (en) 1985-08-16 1989-08-01 Mycogen Corporation Cloning and expression of Bacillus thuringiensis toxin gene toxic to beetles of the order Coleoptera
US5268463A (en) 1986-11-11 1993-12-07 Jefferson Richard A Plant promoter α-glucuronidase gene construct
US5608142A (en) 1986-12-03 1997-03-04 Agracetus, Inc. Insecticidal cotton plants
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5039523A (en) 1988-10-27 1991-08-13 Mycogen Corporation Novel Bacillus thuringiensis isolate denoted B.t. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
JP3046063B2 (ja) 1989-03-17 2000-05-29 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 遺伝子の発現の外部の調節
ATE225853T1 (de) 1990-04-12 2002-10-15 Syngenta Participations Ag Gewebe-spezifische promotoren
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5498830A (en) 1990-06-18 1996-03-12 Monsanto Company Decreased oil content in plant seeds
CA2051562C (en) 1990-10-12 2003-12-02 Jewel M. Payne Bacillus thuringiensis isolates active against dipteran pests
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5399680A (en) 1991-05-22 1995-03-21 The Salk Institute For Biological Studies Rice chitinase promoter
WO1993004177A1 (en) 1991-08-27 1993-03-04 Agricultural Genetics Company Limited Proteins with insecticidal properties against homopteran insects and their use in plant protection
TW261517B (es) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5608144A (en) 1994-08-12 1997-03-04 Dna Plant Technology Corp. Plant group 2 promoters and uses thereof
US5659026A (en) 1995-03-24 1997-08-19 Pioneer Hi-Bred International ALS3 promoter
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
AU762993C (en) 1998-02-26 2004-06-10 Pioneer Hi-Bred International, Inc. Constitutive maize promoters
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
CN1360632A (zh) 1999-05-04 2002-07-24 孟山都技术有限公司 鞘翅目毒性多肽组合物和抗虫转基因植物
CA2384967A1 (en) 1999-09-15 2001-03-22 Monsanto Technology Llc Lepidopteran-active bacillus thuringiensis .delta.-endotoxin compositions and methods of use
US6521901B1 (en) 1999-09-20 2003-02-18 Applied Materials, Inc. System to reduce heat-induced distortion of photomasks during lithography
EP2359869B1 (en) 2001-12-17 2018-12-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor
US20050183161A1 (en) 2003-10-14 2005-08-18 Athenix Corporation AXMI-010, a delta-endotoxin gene and methods for its use
US7629504B2 (en) 2003-12-22 2009-12-08 Pioneer Hi-Bred International, Inc. Bacillus thuringiensis cry9 nucleic acids
ES2397118T3 (es) 2006-06-14 2013-03-04 Athenix Corporation AXMI-031, AXMI-039 ,AXMI-040 y AXMI-049, una familia de genes de endotoxina delta y métodos para su uso
PT2334794T (pt) 2008-09-15 2017-02-15 Harvard College Modulação de bcl11a para tratamento de hemoglobinopatias
WO2011002992A1 (en) 2009-07-02 2011-01-06 Athenix Corp. Axmi-205 pesticidal gene and methods for its use
WO2011084324A2 (en) 2009-12-21 2011-07-14 Pioneer Hi-Bred International, Inc. Novel bacillus thuringiensis gene with lepidopteran activity
CN103154247A (zh) 2010-08-19 2013-06-12 先锋国际良种公司 对鳞翅目昆虫具有活性的新苏云金杆菌基因
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
PT2800811T (pt) * 2012-05-25 2017-08-17 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
HUE030799T2 (en) 2012-07-11 2017-06-28 Sangamo Biosciences Inc Methods and preparations for the treatment of lysosomal storage diseases
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
WO2016033298A1 (en) 2014-08-28 2016-03-03 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
AU2016263026A1 (en) * 2015-05-15 2017-11-09 Pioneer Hi-Bred International, Inc. Guide RNA/Cas endonuclease systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
IL294014B1 (en) 2015-10-23 2024-03-01 Harvard College Nucleobase editors and their uses
EP3426778A1 (en) * 2016-03-11 2019-01-16 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
CA3029141A1 (en) * 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
SG11201906297QA (en) * 2017-03-24 2019-10-30 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US11578323B2 (en) * 2017-12-14 2023-02-14 Bayer Healthcare Llc RNA-programmable endonuclease systems and their use in genome editing and other applications
CN112020554A (zh) * 2018-02-23 2020-12-01 先锋国际良种公司 新颖cas9直系同源物
US20210172008A1 (en) * 2018-04-04 2021-06-10 Lifeedit, Inc. Methods and compositions to identify novel crispr systems
BR112020024863A2 (pt) * 2018-06-05 2022-02-01 Lifeedit Inc Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
US20220096543A1 (en) 2018-12-24 2022-03-31 Virgina Tech Intellectual Properties, Inc. Tollip deficient neutrophils and uses thereof
KR20210149686A (ko) * 2018-12-27 2021-12-09 라이프에디트 테라퓨틱스, 인크. 유전자 편집에 유용한 폴리펩티드 및 사용 방법
CN110551762B (zh) * 2019-08-08 2023-03-10 复旦大学 CRISPR/ShaCas9基因编辑系统及其应用
MX2022001849A (es) * 2019-08-12 2022-03-11 Lifeedit Therapeutics Inc Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.

Also Published As

Publication number Publication date
AU2021258273A1 (en) 2022-12-01
EP4242306A3 (en) 2023-10-18
JP2023516226A (ja) 2023-04-18
US20240026384A1 (en) 2024-01-25
KR20230014700A (ko) 2023-01-30
US20230235360A1 (en) 2023-07-27
BR112022021459A2 (pt) 2023-01-17
CA3174124A1 (en) 2021-10-28
EP4118198A1 (en) 2023-01-18
WO2021217002A1 (en) 2021-10-28
IL297500A (en) 2022-12-01
CN116096879A (zh) 2023-05-09
US20230175018A1 (en) 2023-06-08
TW202208626A (zh) 2022-03-01
US11859181B2 (en) 2024-01-02
US11981916B2 (en) 2024-05-14
US20230257742A1 (en) 2023-08-17
EP4242306A2 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
MX2020013124A (es) Nucleasas guiadas por acido ribonucleico (arn) y fragmentos activos y variantes de los mismos y metodos de uso.
MX2022013187A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
MX2022001849A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
WO2020139783A3 (en) Polypeptides useful for gene editing and methods of use
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
US11746349B2 (en) DNA-guided gene editing and regulation
MX2018012376A (es) Sistemas de replicón de arterivirus recombinantes y usos de estos.
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
EP2864483A1 (en) Transcription activator-like effector assembly
MX2019014516A (es) Metodo para eliminar el gen objetivo en celulas t in vitro y arncr utilizado en el metodo.
MX2022011460A (es) Composiciones y métodos para el direccionamiento de c9orf72.
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
IL309801A (en) Use of protein domains interacting with the nucleosome to enhance targeted genome modification
PH12020551957A1 (en) Codon-optimized acid alpha-glucosidase expression cassettes and methods of using same
WO2009093242A3 (en) Cell populations for polypeptide analysis and uses of same
WO2020025953A3 (en) Nucleic acid construct
MX2019015143A (es) Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso.
MX2023007030A (es) Transposasas programables y usos de las mismas.
EA202092929A1 (ru) Рнк-управляемые нуклеазы и активные фрагменты и их варианты и способы применения
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
AR121909A1 (es) Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso
MX2023007527A (es) Metodos y sistemas para transfeccion celular mejorada.
AR115486A1 (es) Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso
AR120928A1 (es) Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso
MX2021009161A (es) Acidos nucleicos recombinantes que contienen secuencias promotoras de alfaherpesvirus.